Hapvida Earns a “Buy” Rating: Goldman Sachs Sees Bright Future Amidst Operational Gains

Goldman Sachs has elevated its outlook on Hapvida (HAPV3), shifting its recommendation from “neutral” to “buy” and raising the target price from R$4.90 to R$5.70. This optimistic revision follows Hapvida’s impressive first-quarter performance in 2024, showcasing significant improvements in profitability and cash flow. The company’s stock reacted positively, opening up 0.45% at R$4.50, buoyed by […]